Introduction
============

MicroRNAs (miRNAs), being small (∼18--22 nucleotides), endogenous, noncoding RNAs, are involved in various biological roles by negatively regulating mRNA expression at both the posttranscriptional and posttranslational levels.[@b1-bbi-9-2015-089]--[@b3-bbi-9-2015-089] Further, the gene expressions are suppressed by the interaction with their target messenger RNAs (mRNAs), either by blocking the translation process or by initiating the cleavage. Thus, these small regulators have vital roles in numerous biological processes, such as cell differentiation and apoptosis[@b4-bbi-9-2015-089] and also in pathological processes including some of the cancers.[@b5-bbi-9-2015-089]--[@b7-bbi-9-2015-089] The abnormal expression of miRNAs may contribute to either tumor progression (oncomirs) or tumor regression (tumor suppressor) through miRNA--mRNA interactions (MMIs).[@b8-bbi-9-2015-089] So determining the expression and the function of miRNAs in cancers would help to understand their pathogenesis and disease management.

In addition to the transcription factors (coexpressed genes), the dysregulated miRNA--mRNA pairs play a crucial role in cancer formation. To this end, a number of predictive tools, namely, TargetScan,[@b9-bbi-9-2015-089],[@b10-bbi-9-2015-089] PicTar,[@b11-bbi-9-2015-089] miRanda,[@b12-bbi-9-2015-089],[@b13-bbi-9-2015-089] and PITA,[@b14-bbi-9-2015-089] are used to identify the MMIs based on the seed complementarity between miRNAs and the 3′UTRs of specific mRNAs. In addition, these tools also indicate the details of sequence conservation of adjacent bases together with thermodynamic properties of MMIs.[@b15-bbi-9-2015-089] However, there exists a high false discovery rate in determining the miRNA/target mRNA with these tools. This, in turn, underscores the requirement of experimental validation tools including quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot analyses to indicate the functional miRNA and MMIs.[@b16-bbi-9-2015-089]

In the present study, using a simple bioinformatics approach, we have demonstrated two key miRNAs (*miR-486-3p* and *miR-532-5p*) regulating a panel of genes reported earlier in RB tumorigenesis.[@b17-bbi-9-2015-089]--[@b25-bbi-9-2015-089] In this approach, we have considered three groups of genes, namely, Group 1: oncogenes that include high-mobility group-A2 (*HMGA2*),[@b24-bbi-9-2015-089] *N*-myc proto-oncogene protein (*MYCN*),[@b19-bbi-9-2015-089] spleen tyrosine kinase (*SYK*),[@b25-bbi-9-2015-089] fatty acid synthase (*FASN*)[@b23-bbi-9-2015-089]; Group 2: genes involved in cancer cell stemness, which include epithelial cell adhesion molecule (*TACSTD1*),[@b21-bbi-9-2015-089] ATP-binding cassette sub-family G member 2 (*ABCCG2*),[@b22-bbi-9-2015-089] cluster of differentiation 24 (*CD24*),[@b20-bbi-9-2015-089] *CD133*, and *CD44*[@b17-bbi-9-2015-089]; and Group 3: cell cycle regulatory genes, which includes *TP53* and *MDM2* (mouse double minute 2 homolog).[@b18-bbi-9-2015-089] An in silico approach using the predictive tools including Microcosm, DIANALAB, miRBase v18, REFSEQ database, and RNA Hybrid was used to determine MMIs. Further, the identified miRNAs' role in RB tumorigenesis has been addressed by *in vitro* experimental validations using RB cell lines (Y79 and Weri Rb1).

Material and Methods
====================

In silico analysis to predict miRNAs regulating a panel of genes reported in RB
-------------------------------------------------------------------------------

A comprehensive bioinformatic analysis was carried out to find the list of miRNAs that could target and are likely to be involved in posttranslational regulation of widely reported genes in RB progression. The select panel of genes were divided into three groups based on the functions, namely, Group 1: oncogenes (*HMGA2, MYCN, SYK, FASN*); Group 2: cancer stem cell markers (*TACSTD1, ABCG2, CD133, CD44, CD24*); and Group 3: cell cycle regulatory proteins (*p53* and *MDM2*). The known, predicted, and validated miRNAs that could target any of these groups of genes in Groups 1, 2, and 3 were obtained from the following databases: Microcosm (<http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/>)DIANALAB (<http://diana.cslab.ece.ntua.gr/DianaTools> New/index.php?r=tarbase)miRBase v18 (<http://www.mirbase.org/>)REFSEQ database ([www.ncbi.nlm.nih.gov/RefSeq/](http://www.ncbi.nlm.nih.gov/RefSeq/))RNA Hybrid.

miRNAs targeting the selected genes were considered based on their MFE (minimal free energy of ≤−30 and a *P*-value of ≤0.05). Further, using the miRanda algorithm, the detailed complementary alignment between 5′ seed sequence of differentially expressed miRNAs and the sequence of target genes were determined.

Some of the other genes regulated by these two miRNAs (*miR-486-3p* and *miR-532-5p*) were predicted using the online tools Target scan (<http://www.targetscan.org> version 5.2), pic-TAR (<http://pictar.mdc-berlin.de>), and microcosm (<http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/>).

Primary RB tumor tissues
------------------------

This study was reviewed and approved by the institutional ethics committee of Vision Research Foundation, Sankara Nethralaya (Ethics number: 249b-2011-P). The study was conducted in accordance with the principles of the Declaration of Helsinki.

RB primary tumor samples were collected from 30 enucleated eyeballs of RB patients as part of RB management during 2011--2012. The study included 15 male and 15 female patients with a median age of 2.5 years. Grading of the tumors was performed from the microscopic observations of hematoxylin and eosin (H&E)-stained RB sections by an ocular pathologist. Histopathological information, namely, tumor invasion of the choroid, optic nerve, or orbit ([Table 4](#t4-bbi-9-2015-089){ref-type="table"}), was obtained from surgical pathology reports. Among the tumors analyzed, there were 17 invasive tumors and 13 noninvasive tumors, which included 8 differentiated and 22 undifferentiated tumors with high-risk histopathological features. Based on the clinical presentation of the patients, the tumors were classified as per the International Intraocular Retinoblastoma Classification (IIRC): there were 9 tumors in group E, 15 tumors in group D, and 6 tumors in group B.[@b26-bbi-9-2015-089] There were 8 invasive and 1 noninvasive tumors in group E, 5 invasive and 10 noninvasive in group D, and 4 invasive and 2 noninvasive in group B. Normal adult retinas collected from five cadaveric eyeballs (received at the C.U. Shah eye bank, Sankara Nethralaya, <http://www.sankaranethralaya.org/eye-bank.html>) during the year 2012 were included in the study.

Cell lines
----------

Human RB Cancer cell lines (Y79 and Weri Rb1; Riken cell bank, Japan) were used in this study. The RB cell lines were cultured with supplementation of 10% heat-inactivated fetal calf serum (Gibco-BRL), 0.1% ciprofloxacin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 4.5% dextrose (Sigma Aldrich) in Roswell Park Memorial Institute 1640 medium (Gibco-BRL).

Treatment of miRNA mimics in RB cells
-------------------------------------

The description of miRNA mimics used in the study is given in [Table 1](#t1-bbi-9-2015-089){ref-type="table"}. About 1 × 50,000 cells were plated per well (12-well plates) and allowed to grow for 24--36 hours (until they were 40%--60% confluent). They were transfected with 0.5 mL antibiotic-free media containing 50 pmol of specific miRNAs mimics plus the corresponding concentration of transfection reagent (Lipofectamine™ 2000) for 24, 48, and 72 hours. After incubation, the cells were harvested and processed for further analysis. The same protocol was applied using nontarget scrambled miRNA as transfected control.

miRNA/gene expression analysis by qRT-PCR in RB primary tumors and miRNA mimic-treated RB cells
-----------------------------------------------------------------------------------------------

Total RNA isolation from the RB primary tumor tissues (*n* = 30) was carried out as per manufacturer's instructions by using the miRCURY RNA Isolation Kit (cat. number 300111, Exiqon). Polyadenalation and complementary strand synthesis of 100 ng of total RNA was carried out as per manufacturer's instruction using the cDNA synthesis kit (cat. no. 203450, Exiqon). The presence of miRNAs in 5 ng of cDNA was determined using miRNA-specific primers and SYBR Green master mix in the primary RB tumors and in cell lines as per manufacture's protocol. The LNA primers used in this study are tabulated in [Table 2](#t2-bbi-9-2015-089){ref-type="table"}. Complementary strand synthesis for the gene expression studies was carried out using oligo dT as random primers and 1 μg of total RNA (Sensiscript II; cat. no. 205211, Qiagen). Gene expression levels of *SYK* and *FASN* in the transcribed cDNA was determined using syber green master mix (cat. no. 330500, Qiagen). The primers of *SYK*: FP: 5′GGAAGTGAAGTCACCGCTATG3′; RP: 3′GGGAGCGGTTAGTTCACCAC5′, and *FASN*: FP: 5′CG ACAGCACCAGCTTCGCCA3'; RP: 5′CACGCT-GGCCTGCAGCTTCT3′. The commercial software SDS ver.1.3; ABI was used to calculate ∆∆Ct.[@b27-bbi-9-2015-089] Relative expression values for genes/miRNA were normalized to GAPDH/RNU6B as endogenous control. The unit of fold change was expressed in log~2~ transformed ratios.

Western blot analysis of SYK and FASN proteins in miRNA mimic-treated RB cells
------------------------------------------------------------------------------

The total protein cell lysate of miRNA mimics in RB cells was extracted using RIPA lysis buffer \[50 mM Tris-HCl (pH 7.6), 5 mM EDTA, 150 mM sodium chloride, 0.1% phenylmethanesulfonyl fluoride (PMSF), and 250 μL of 1 mg/mL protease inhibitor cocktail\] on ice. A total of 25 μg protein was resolved by using 10% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) for SYK protein and 8% SDS-PAGE for FASN protein expression. Following protein electrophoresis, the separated proteins were transferred onto nitrocellulose membranes at 100 V for one hour. After blocking the membrane with 5% skimmed milk for one hour, the blots were incubated with the specific primary antibody \[SYK (cat. no. ab 57465, Abcam:) 1:1000; FASN (cat. no. 610962, BD Biosciences): 1:250\] overnight at 4 °C followed by the corresponding horseradish peroxidase-conjugated secondary antibody (1:4000) and incubated for two hours. After intermittent washes with Tween Tris-buffered saline, the membranes were subjected to chemiluminescence detection (SuperSignal West Femto Maximum Sensitivity Substrate). Intensity of the bands was measured densitometrically (Quantity One, version 4.7 software using GS-800 calibrated densitometer, Bio-Rad) and normalized with the respective β-actin expression to derive the protein concentration in the individual samples. This relative band intensity quantification was done using Image J software.

Measurement of cell viability using MTT assay in miRNA mimic-treated RB cells
-----------------------------------------------------------------------------

The cell viability in the mimic-transfected RB cells was analyzed by using 3-(4,5-dimethylthiazolyl) 2,5diphenyltetrazolium bromide (MTT) assay. About 5,000 cells/96 wells were transfected with 50 pmol of miRNA mimics and scramble mimics. Following 24, 48, and 72 hours of transfection, serum-free RPMI medium containing 10 μL of 5 mg/mL MTT was added and incubated at 37 °C in a CO~2~ incubator for four hours. The formed formazan crystals were dissolved in 100 μL dimethylsulfoxide (DMSO), and the absorbance was measured spectrophotometrically at 570 nm (Beckman Coulter); the background was subtracted at 650 nm. Assay was performed in triplicates with and without scramble miRNA as controls.

Measurement of apoptosis using annexin-V-FLUOS stain in miRNA mimic-treated RB cells
------------------------------------------------------------------------------------

About 2 × 10^5^ cells/12-well plate were transfected with 50 pmol miRNA mimics and scramble mimics and incubated at 37°C in a CO~2~ incubator for 48 hours. At the end of incubation, the cells were collected, washed, and processed for the apoptosis assay using the annexin-V-FLUOS apoptosis detection kit (cat. no. 556547, BD Pharminogen) as per the manufacturer's instructions. The percentage of apoptotic cells in the experimental groups was determined by using a flow cytometer (FACS Calibur, Becton-Dickinson).

Measurement of change in cell cycle using propidium iodide stain in miRNA mimic-treated RB cells
------------------------------------------------------------------------------------------------

In order to determine the effect of mimic treatment in RB cells, 50 pmol miRNA mimics and scramble mimics were transfected in 2 × 10^5^ cells/12-well plate and incubated at 37 °C in a CO~2~ incubator for 48 hours. At the end of incubation, the cells were collected, washed twice with ice-cold 1 × PBS, fixed for 30 minutes with 70% cold ethanol twice, and then incubated at 37 °C for 2 hours in 1 × PBS buffer containing 100 μg/mL RNase A and 5 μg/mL propidium iodide. Following staining, the cells were washed and the percentage of cells at various cell cycle phases was determined using the flow cytometer.

Statistical analysis
--------------------

One-way ANOVA, post hoc Dunnet T-test, independent *t*-test, and Mann--Whitney U-test were performed to compare the variables of *in vitro* experiments and of RB primary tumors. Paired Student's *t*-test was used to compare the miRNA expressions in control and experimental groups of *in vitro* studies.

Results
=======

Identification of miRNAs regulating the most candidate genes involved in RB tumorigenesis
-----------------------------------------------------------------------------------------

From the comprehensive bioinformatics analysis, the number of miRNAs that are likely to be involved in posttranslational regulation of Group I genes (*HMGA2, MYCN, SYK, FASN*) were identified as 5004, Group II genes (*TACSTD1, ABCG2, CD133, CD44, CD24*) as 4804 miRNAs, and Group III genes (*p53 and MDM2*) as 7261 miRNAs. In order to remove redundancy, filtration of all the identified miRNAs was carried out, after which 1948 miRNAs were obtained. Further, in order to determine the miRNAs relevant to RB tumoriogenesis, the identified 1948 miRNAs were intersected with the miRNAs involved in RB tumoriogenesis reported earlier in serum samples.[@b28-bbi-9-2015-089] From this intersection, we observed only nine upregulated miRNAs, which include *miR-146b-5p, miR-305, miR-663b, miR-299, miR-532-5p, miR-892b, miR-501, miR-142-5p*, and *miR-513b*. In addition, we again observed only 10 downregulated miRNAs, which include *miR-1254, miR-328, miR-133a, miR-1287, miR-1299, miR-375, miR-486-3p, miR-720, miR-98*, and *miR-122*\*.

Further, from this list of miRNAs, the highly regulated miRNAs are filtered based on their MFE (≤−30, *P*-value ≤0.05) and those reported in the Microcosm and DIANA LAB databases ([Table 3](#t3-bbi-9-2015-089){ref-type="table"}). Based on these results, three miRNAs were selected, namely, *miR-146b-5p, miR-532-5p*, and *miR-142-5p*, from the upregulated miRNAs panel and two miRNAs, namely, *miR-328* and *miR-486-3p*, from the down-regulated list for validation in RB primary tumor tissues.

miRNA expression in RB primary tumor tissues and in normal cadaveric adult donor retina
---------------------------------------------------------------------------------------

The miRNA expression analysis in RB primary tumor tissues (*n* = 30) by qRT-PCR revealed a median fold change of *miR-486-3p* (in the order of invasion = −1.26, no invasion = −1.07), *miR-532-5p* (in the order of invasion = −0.69, no invasion of = −1.00), *miR-142* (in the order of invasion = −0.18, no invasion = −0.17), *miR-146b* (in the order of invasion = −0.73, no invasion = −0.87), and *miR-328* (in the order of invasion = −0.70, no inva sion = −0.59). The miRNA expression of RB tumor tissues relative to normal cadaveric donor retina with the clinicopathological description is given in [Table 4](#t4-bbi-9-2015-089){ref-type="table"}. The median fold change of all these five miRNAs in normal cadaveric adult donor retina is in the following order: *miR-486-3p*, −0.14; *miR-532-5p*, −0.01; *miR-142*, 0.24; *miR-146b*: 0.14, and *miR-328*, 0.19 ([Table 5](#t5-bbi-9-2015-089){ref-type="table"}). Interestingly, we observed a downregulation of all the validated miRNAs relative to the normal donor retina. No significant association of the miRNA expression with that of normal retina was observed.

miRNA expression in RB cell lines (Y79 and Weri Rb1)
----------------------------------------------------

The median fold change of all these five miRNAs in Y79 is in the order *miR-486-3p*, −1.92; *miR-532-5p*, −1.76; *miR-142*, −0.98; *miR-146b*, −1.39; and *miR-328*, −2.09 while in Weri Rb 1 it is in the order *miR-486-3p*, −1.86, *miR-532-5p*, −1.77; *miR-142*, −0.86, *miR-146b*, −1.87; and *miR-328*, −1.92. Taken together, the miRNA expressions in primary RB tumor tissues and in cell lines, the two miRNAs with high fold decrease, namely, *miR-486-3p* and *miR-532-5p*, were selected for the *in vitro* functional analysis using RB cell lines Y79 and Weri Rb1. Based on the miRSVR scores, the gene targets of these two miRNAs, namely, *SYK* (*miR-532-5p*: miRSVR score = −0.0080 and *miR-486-3p*: miRSVR score = −0.0283) and *FASN* (*miR-532-5p*: miR-SVR score = −0.0013 and *miR-486-3p*: miRSVR = −0.0008) were selected for further *in vitro* validations.

Functional analysis of the select miRNAs in RB cell lines
---------------------------------------------------------

Since we observed downregulation of *miR-486-3p* and *miR-532-5p*, we carried out the addition of miRNA mimics to the RB cells, which would enable us to better understand the MMI. The nontargeting mimic was used as the scramble control in miRNA mimic experiments.

Gene expression in mimic-transfected RB cells
---------------------------------------------

The RB cells were transfected with 50 pmol of mature miRNA sequences (mimics) *miR-486-3p* and *miR-532-5p* and the scramble negative control. After 48 hours of transfection, the levels of *SYK* and *FASN* mRNAs were analyzed in comparison with the scramble transfected control. The mean expression levels of *SYK* and *FASN* mRNA expression in mimic-transfected Y79 and Weri Rb1 cells at the end of 24, 48, and 72 hours of incubation are given in [Table 6](#t6-bbi-9-2015-089){ref-type="table"}.

These results indicate a significant decrease of *SYK* and *FASN* mRNAs by −2.2 and −2.6-fold change in *miR-486-3p* mimic-transfected Y79 cells at end of 48 hours of incubation. Similarly, a decrease of *SYK* and *FASN* mRNAs by −4.7- and −1.2-fold change in *miR-532-5p* mimic-transfected Y79 cells was seen at the end of 48 hours of incubation. In Weri Rb1, *miR-486-3p* mimic transfection resulted in the decrease of *SYK* and *FASN* mRNAs by −3.4- and −0.3-fold change at the end of 48 hours of incubation, while *miR-532-5p* mimic transfection resulted in the decrease of *SYK* and *FASN* mRNAs by −8.7- and −1.7-fold change at the end of 48 hours of incubation, respectively. In addition, these results indicate the better downregulation of the regulatory mRNAs (*SYK* and *FASN*) at the end of 48 hours of incubation compared to the other time points (24 and 72 hours). Thus, 50 pmol concentration of mimics and 48 hours of incubation were selected for the further experiments.

Change of SYK and FASN protein expression in miRNA-mimic transfected RB cells
-----------------------------------------------------------------------------

The decrease in *SYK* and *FASN* mRNA in *miR-486-3p* and *miR-532-5p* mimic-transfected RB cells was confirmed with the protein expression using western blot analysis. We observed a decrease of ∼30% of SYK and ∼20% FASN proteins in *miR-486-3p* transfected Y79 cells and 30% of SYK and 20% FASN in *miR-532-5p* transfected Y79 cells compared to scramble transfected Y79 cells after 48 hours of incubation. Similarly, we observed a decrease of ∼35% of SYK and ∼25% of FASN protein in *miR-486-3p* transfected Weri Rb1 cells and ∼ 35% of SYK and ∼25% of FASN in *miR-532-5p* transfected Weri Rb1 cells compared to scramble transfected Weri Rb1 cells after 48 hours of incubation.

Decrease of cell viability in mimic-transfected RB cells
--------------------------------------------------------

In Y79 cells, the treatment with *miR-486-3p* mimics resulted in a reduction of cell viability to 86.08%, 58.42%, and 66.86% at the end of 24, 48, and 72 hours of incubation, respectively. The treatment with *miR-532-5p* of Y79 cells resulted in the decrease of cell viability to ∼88.97%, 71.05%, and 77.8%, while the scramble transfected negative control showed a cell viability of 94.2%, 82.2%, and 80.84% at the end of 24, 48, and 72 hours of incubation, respectively, compared to untransfected cell control.

Similarly, in Weri Rb 1, the treatment of *miR-486-3p* mimics resulted in a reduction of cell viability to 90.41%, 66.41%, and 51.74% at the end of 24, 48, and 72 hours of incubation, respectively. The treatment with *miR-532-5p* of Weri Rb1 cells resulted in a decrease of cell viability to ∼87.63%, 72.47%, 56.39%, while the scramble transfected negative control showed a cell viability of 96.51%, 86.51%, and 89.78% at the end of 24, 48, and 72 hours of incubation, respectively, compared to untransfected control cells.

Increase of apoptosis in mimic-transfected RB cells
---------------------------------------------------

In Y79 cells, the annexin assay revealed that treatment with *miR-486-3p* and *miR-532-5p* mimics resulted in the induction of late apoptotic cells to about 30.9% and 30.6%, while the scramble mimic treatment resulted in 2.62% compared to the untransfected cell control, at the end of 48 hours of incubation. Similarly, treatment with *miR-486-3p* and *miR-532-5p* mimics in Weri Rb1 cells resulted in the induction of late apop-totic cells to about 19.6% and 21.8%, while the scramble mimic treatment resulted in 13.5% compared to the untransfected control cells at the end of 48 hours of incubation. A significant change (*P*-value \<0.05) in the percentage of cell viability in *miR-486-3p* and *miR-532-5p*-mimic treated Y79 cells was observed.

Alteration of cell cycle phases in the mimic-transfected RB cells
-----------------------------------------------------------------

In Y79 cells, treatment with *miR-486-3p* and *miR-532-5p* mimics resulted in altered percentage of G2/S phase cells to ∼48.7% and 48.7%, respectively, while treatment with the scramble mimics resulted in 30.5% at the end of 48 hours of incubation. Similarly, treatment with *miR-486-3p* and *miR-532-5p* mimics of Weri Rb1 resulted in the alteration of G~2~/S phase cells to ∼53.1% and 54.9%, respectively, while treatment with the scramble mimics resulted in 47.9% at the end of 48 hours of incubation. Though a significant change of G~2~ /S phase cell percentage was observed in Y79 cells, no significant change was observed in Weri Rb1 cells.

Discussion
==========

The standard methodology to perform functional analysis of MMIs would require array-based mRNA and miRNA global expressions or RNA sequencing inputs. These approaches would require large investment, including a huge quantity of purified RNA and the economic resources to perform two different arrays, which in turn limits number of paired miRNA--mRNA datasets in the available public repositories.[@b29-bbi-9-2015-089] Thus data mining from these repositories would provide immediate information about the paired miRNA--mRNA networks and their gene target regulations.

In this study, we used an in silico approach to identify miRNAs regulating the panel of genes \[categorized as Group I genes (*HMGA2, MYCN, SYK, FASN*), Group II genes (*TACSTD1, ABCG2, CD133, CD44, CD24*), and Group III genes (*p53* and *MDM2*) involved in RB tumoriogenesis; [Figure 1](#f1-bbi-9-2015-089){ref-type="fig"}\]. With the removal of redundancy, 1948 common miRNAs were obtained from this miRNA approach. Further, the comparison of these miRNAs with the reported RB serum miRNA expression profile[@b28-bbi-9-2015-089] revealed 9 upregulated miRNAs (*miR-146b-5p, miR-305, miR-663b, miR-299, miR-532-5p, miR-892b, miR-501, miR-142-5p*, and *miR-513b*) and 10 downregulated miRNAs (*miR-1254, miR-328, miR-133a, miR-1287, miR-1299, miR-375, miR-486-3p, miR-720, miR-720, miR-98*, and *miR-122*\*). However, in order to rule out the false discovery rate of the current study, five miRNAs (upregulated panel, *n* = 3: *miR-146b-5p, miR-532-5p*, and *miR-142-5p* and downregulated panel, *n* = 2: *miR-328* and *miR-486-3p*) were selected for *in vitro* experimental validation using qRT-PCR.

However, the miRNA expression analysis using qRT-PCR revealed a higher downregulation of two miRNAs, namely *miR-486-3p* (median fold change in the order of invasion = −1.26, no invasion = −1.07) and *miR-532-5p* (median fold change in the order of invasion = −0.69, no invasion = −1.00) compared to the normal cadaveric donor retina. The regulatory genes of these two key miRNAs (*miR-486-3p* and *miR-532-5p*) are *SYK* and *FASN*. Filtration of gene targets of these miRNAs was based on their MFE of ≤−30 and *P*-value of ≤0.05 and those reported in Microcosm and DIANA LAB databases ([Table 3](#t3-bbi-9-2015-089){ref-type="table"}). Similarly, we observed downregulation of these miRNAs in two of the RB cell lines, namely Y79 and Weri Rb1 ([Tables 4](#t4-bbi-9-2015-089){ref-type="table"} and [5](#t5-bbi-9-2015-089){ref-type="table"}; [Fig. 2B](#f2-bbi-9-2015-089){ref-type="fig"}). Downregulated *miR-486-3p* has been known to contribute to aggressive lung cancer with lymphnode metastasis[@b30-bbi-9-2015-089]--[@b32-bbi-9-2015-089] and also reported to be a biomarker in the primary non-small-cell lung carcinoma (NSCLC) tissues and plasma[@b32-bbi-9-2015-089] and gastric cancer progression.[@b33-bbi-9-2015-089] Further, lowered *miR-486-3p* and *miR-532-5p* have been reported in renal cell carcinoma.[@b34-bbi-9-2015-089] These reports in other cancers together corroborate the current results of lowered *miR-486-3p* and *miR-532-5p* expression in RB. However, interestingly, higher expression of *miR-532-5p* is reported in the RB serum samples (*n* = 14). The small sample size could be one of the factors responsible for the variation among these results.[@b28-bbi-9-2015-089]

In order to study the functional role of these two miRNAs in RB progression and their regulation of *SYK* and *FASN* as gene targets, *in vitro* experiments using miRNA mimics were performed. Using the classical approach, mRNA and protein levels of the target genes were quantified in RB cells treated with miRNA mimics (*miR-486-3p* and *miR-532-5p*) in comparison with scramble mimics.[@b16-bbi-9-2015-089],[@b35-bbi-9-2015-089] From these experiments, we observed an inverse correlation of *SYK* and *FASN* mRNA expression in RB cells transfected with the mimics, especially at the end of 48 hours of incubation ([Table 5](#t5-bbi-9-2015-089){ref-type="table"}, [Fig. 3](#f3-bbi-9-2015-089){ref-type="fig"}). The reduced SYK and FASN protein expression in mimic-transfected RB cells compared to the scrambled control corroborates the mRNA downregulation of mimic-transfected RB cells ([Fig. 4](#f4-bbi-9-2015-089){ref-type="fig"}). Earlier reports have shown the significant role of these two genes in other cancers such as breast cancer[@b36-bbi-9-2015-089] and, especially, RB.[@b23-bbi-9-2015-089],[@b25-bbi-9-2015-089],[@b37-bbi-9-2015-089] Zhang et al have reported the upregulation of the protooncogene *SYK* with its importance in RB cell survival and indicated *SYK* as a promising therapeutic target.[@b25-bbi-9-2015-089] Further, *FASN* was reported as a potential therapeutic target in RB management with its marked overexpression in invasive tumors.[@b23-bbi-9-2015-089]

Further, the chemical inhibitors of the FASN enzyme in RB cells have resulted in apoptosis in RB cells.[@b38-bbi-9-2015-089],[@b39-bbi-9-2015-089] These earlier studies corroborate our current results of reduced cell proliferation and increased apoptosis due to lowered *SYK* and *FASN* expression in miRNA mimic-transfected RB cells relative to scramble treated control cells ([Figs. 5](#f5-bbi-9-2015-089){ref-type="fig"} and [6](#f6-bbi-9-2015-089){ref-type="fig"}). We also observed mild morphological changes such as a decrease in RB cell size (image not shown) in RB cells treated with miRNA mimics *miR-486-3p* and *miR-532-5p* compared to the scramble treated control cells. These morphological changes in cells may be attributed to the metabolic changes, induction of apoptosis, cellular senescence, and cellular degeneration due to increase of cellular miRNAs (*miR-486-3p* and *miR-532-5p*). Taken together, the current results of *SYK* and *FASN* downregulation in mimic-transfected RB cells indicate the role of these oncogenes in RB cell growth.

Using the gene target prediction tools Target scan, picTAR, and Microcosm, the genes involved in cell migratory function contributing to the invasion and metastases were listed.

Some of these genes are as follows: *TSPAN9*, *SOX10*, *SOX12*, *ADAM19*, and *ITGA11* (regulated by *miR-486-3p*); *ADAM22*, *ITGA11*, *CDC42*, *IGF1R*, *SMAD2*, and *SMAD5* (regulated by *miR-532-5p*). Among these genes, the suppression of *TSPAN9*, *SOX10*, *ITGA11*, and *CDC42* are reported to inhibit cellular migration in other cancers. Earlier reports have indicated the deregulation of *TSPAN9* (*CD9*) and *CDC42* in prostate cancer,[@b40-bbi-9-2015-089],[@b41-bbi-9-2015-089] *SOX10* in cutaneous melanoma,[@b42-bbi-9-2015-089] and *ITGA11* through the suppression of integrin-mediated signaling pathway in nasopharyngeal carcinoma.[@b43-bbi-9-2015-089] Thus, these predicted genes implicated by the in silico tools can be validated in future for cell migration function.

Further, the cell cycle analysis in mimic-transfected RB cells pointed to a marked change in the G~2~/S phase of the Y79 cells (∼48.7% and 48.7%), and the scramble mimic treatment resulted in 30.5% of G~2~/S phase of cell cycle, while no marked cell cycle phase was observed in mimic-transfected Weri Rb 1 cells ([Fig. 7](#f7-bbi-9-2015-089){ref-type="fig"}). The difference in aggressive phenotypes that exists between the two cell lines may be responsible for the variation in this cell cycle results among the mimic-transfected RB cell lines.

Conclusion
==========

We have reported the downregulation of *miR-486-5p* and *miR-532-5p* in primary RB tumors, implicating their role in RB tumorigenesis and their prognostic potential. The downregulation of the gene targets *SYK* and *FASN* at the transcript level and protein level in the presence of miRNA mimics confirmed the miRNA--mRNA regulatory relationship. Mimic-mediated overexpression of *miR-486-3p* and *miR-532-5p* resulted in apoptotic cell death of RB cancer cells, suggesting its beneficial role in RB control.
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**Supplementary File.** This EXCEL file indicates the list of gene targets determined by comprehensive analysis of miRNA--mRNA networks. The worksheets provide the interaction between the miRNAs and mRNAs as scores ranging from 1 to 4 based on their sequence-based interaction. The databases Microcosm, DIANALAB, miRBase v 18, REFSEQ database, and RNA hybrid were used to predict the posttranscriptional regulators (miRNAs) of the select panel of genes (\[Group 1: oncogenes (*HMGA2, MYCN, SYK, FASN*); Group 2: cancer stem cell markers (*TACSTD1, ABCG2, CD133, CD44, CD24*) and Group 3: cell cycle regulatory proteins (p53 and MDM2\]). Further, the work sheet provides the summary of the predicted miRNAs interception with miRNA profiling of retinoblastoma serum samples reported earlier.
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![Schematic representation of the steps followed in the identification of miRNAs regulating the panel of candidate genes involved in RB progression. (**A**--**C**) Classification of a panel of genes regulating the RB tumoriogenesis as Group 1: oncogenes (*HMGA2, MYCN, SYK, FASN*); Group 2: cancers stem cell markers (*TACSTD1, ABCG2, CD133, CD44, CD24*), and Group 3: cell cycle regulatory proteins (*p53* and *MDM2*). (**D**) Identification of the miRNA--mRNA targets using Microcosm, DIANALAB, miRBase v18, REFSEQ database, and RNA Hybrid. (**E**) Reducing redundancy and filtering of 1948 miRNAs. (**F**) Intersection with miRNA profiling (serum samples). (**G**) Derived upregulated (*n* = 9) and downregulated (*n* = 10) miRNAs. (**H**) Filtering based on their MFE (minimal free energy of ≤−30 and *P*-value of ≤0.05) reported in MICROCOSM and DIANA LAB databases. (**I**) miRNA expression in RB tissues (*n* = 30)/normal retina (*n* = 5) using qRT-PCR. (**J**) functional evaluation of two miRNAs using mimics (RB cell lines).](bbi-9-2015-089f1){#f1-bbi-9-2015-089}

![Graphical representation of select miRNA expression in (**A**) RB primary tumors (invasion, *n* = 17 and no invasion *n* = 13) and in normal cadaveric adult retinae (*n* = 5) and (**B**) RB cell lines (Y79 and Weri Rb1), Fold change of the miRNAs is in the order of *miR-486-3p* (blue bar), *miR-532-5p* (red bar), *miR-142-5p* (green bar), *miR-146b-5p* (purple bar), and *miR-328* (yellow bar). Error bars represent the standard deviation of three experiments.](bbi-9-2015-089f2){#f2-bbi-9-2015-089}

![Graphical representation of *SYK* and *FASN* mRNA in mimic-transfected RB cells. The bar graph represents relative expression of *SYK* (blue) and *FASN* (red) in 50 pmol of *miR-486-3p* and *miR-532-5p* mimics transfection. Fold change in transfected RB cells are derived relative to scramble transfected control at the end of 24, 48, and 72 hours of incubation. Error bars represent the standard deviation of three experiments,\
**Notes:** \*\**P*-value \<0.01. **A**: Y79 and **B**: Weri Rb1.](bbi-9-2015-089f3){#f3-bbi-9-2015-089}

![Protein expression in miRNA mimic-transfected RB cells. (**A**) Western blot analysis of FASN and SYK proteins in miRNA mimic-transfected RB cells. Lanes 1--3: Scramble control, *miR-486-3p* and *miR-532-5p* mimic-transfected Y79 cells. Lanes 4--6: Scramble control, *miR-486-3p* and *miR-532-5p* mimic-transfected Weri Rb1 cells. (**B** and **C**) Bar graph representing the percentage of proteins FASN and SYK in *miR-486-3p* and *miR-532-5p* mimic-transfected RB cells (Y79 and Weri Rb 1). Error bars represent the standard deviation of two experiments.](bbi-9-2015-089f4){#f4-bbi-9-2015-089}

![Graphical representation of cell viability assay using MTT. Percentage of cell viability in 50 pmol of *miR-486-3p* and *miR-532-5p* mimic-transfected RB cells (**A**) Y79 and (**B**) Weri Rb1 at the end of 24, 48, and 72 hours of incubation. The four lines indicate in the order of untransfected control (blue), scramble control (red), *miR-486-3p* (green), and *miR-532-5p* (purple). Error bars represent the standard deviation of three experiments.\
**Notes:** \*\**P*-value \<0.01; \**P*-value \<0.05.](bbi-9-2015-089f5){#f5-bbi-9-2015-089}

![Scatter plot of apoptotic cells in scramble control and mimics transfected RB cells. (**A**) Y79, (**B**) Weri Rb1. Overlay graph of scramble control and mimic-transfected RB cells (**C**) Y79, (**D**) Weri Rb1. In the overlay graph, black line indicates unstained cells, green line indicates untransfected cells, pink line indicates *miR-486-3p*-transfected cells, and blue line indicates *miR-532-5p*-transfected cells.](bbi-9-2015-089f6){#f6-bbi-9-2015-089}

![Scatter plot of cell cycle analysis stained by propidium iodide stain in 50 pmol of mimics at the end of 48 hours of incubation. (**A**) Measurement of various cell cycle stages in mimic-treated Y79 cells. (**B**) Measurement of various cell cycle stages in mimic-treated Weri Rb 1 cells. The bar graph shows RB cells at various stages of cell cycle in scramble and mimic-treated RB cells. Error bars represent the standard deviation of three experiments.](bbi-9-2015-089f7){#f7-bbi-9-2015-089}

###### 

Details of miRIDIAN microRNA mimics with the mature sequence and accession number.

  S.NO   miRIDIAN microRNA MIMICS, CAT. NO (DHARMACON, THERMO FISHER SCIENTIFIC-INDIA)                                         MATURE SEQUENCE AND ACCESSION NUMBER
  ------ --------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  1\.    Mimic Negative control (Based on *cel-miR-67*, as they have minimal identity with miRNAs in humans. CN-001000-01-20   UCACAACCUCCUAGAAAGAGUAGA (MIMAT0000039)
  2\.    Human *hsa-miR-486-3p*--Mimic, C-301211-01-0010                                                                       CGGGGCAGCUCAGUACAGGAU (MIMAT0004762)
  3\.    Human *hsa-miR-532-5p*--Mimic, C-300867-01-0010                                                                       CAUGCCUUGAGUGUAGGACCGU (MIMAT0002888)

###### 

Details of miRIDIAN miRNA primers (LNA, Exiqon, USA).

  S.NO   PRODUCT NUMBER   PRODUCT NAME, microRNA PRIMER SET.   TARGET SEQUENCE          TARGET SEQUENCE ACCESSION NUMBER
  ------ ---------------- ------------------------------------ ------------------------ ----------------------------------
  1\.    202353           *hsa-miR-486-3p*                     CGGGGCAGCUCAGUACAGGAU    MIMAT0004762
  2\.    202435           *hsa-miR-532-5p*                     CAUGCCUUGAGUGUAGGACCGU   MIMAT0002888
  3\.    202074           *hsa-miR-328*                        CUGGCCCUCUCUGCCCUUCCGU   MIMAT0000752
  4\.    202274           *hsa-miR-146b-5p*                    UGAGAACUGAAUUCCAUAGGCU   MIMAT0002809
  5\.    204722           *hsa-miR-142-5p*                     CAUAAAGUAGAAAGCACUACU    MIMAT0000433

###### 

miR-SVR scores and the position on the mRNA sequence for the selected five miRNAs and their posttranslational regulatory genes.

  S.NO                GENE                                        miRNA SHOWING HITS ON THE GENE   SVR SCORE                            POSITION ON mRNA SEQUENCE
  ------------------- ------------------------------------------- -------------------------------- ------------------------------------ ---------------------------
  1\.                 *FASN*                                      *hsa-miR-532-5p*                 −0.0013                              137, 464
  *hsa-miR-146b-3p*   −0.0077                                     538                                                                   
  *hsa-miR-328*       −0.0004                                     498                                                                   
  *hsa-miR-486-3p*    −0.0008,−0.046, −0.1287                     1, 110, 393                                                           
  2\.                 *HMGA2*                                     *Has-miR-142-3p*                 −0.6633,                             545, 1228, 1547, 2499
  *hsa-miR-328*       −0.0281, −0.811, −0.5492−0.0130             2093                                                                  
  3\.                 *MYCN*                                      *hsa-miR-532-3p*                 −0.0006                              239
  4\.                 *SYK*                                       *hsa-miR-532-5p*                 −0.0080                              1574
  *hsa-miR-146b-3p*   −0.0005                                     2594                                                                  
  *hsa-miR-486-3p*    −0.0283                                     2421                                                                  
  5\.                 *ABCG2*                                     *hsa-miR-532-5p*                 −0.1924, −0.0032                     590, 659
  *hsa-miR-146b-5p*   −0.7574, −0.5036                            910, 1819                                                             
  *hsa-miR-142-5p*    −0.5511, −0.5931                            361, 897                                                              
  *hsa-miR-328*       −0.0445                                     602                                                                   
  *hsa-miR-486-5p*    −0.0083                                     1533                                                                  
  6\.                 *CD24*                                      *hsa-miR-532-5p*                 −0.0076                              711
  *hsa-miR-142-5p*    −0.0202                                     1677                                                                  
  *hsa-miR-146b-5p*   −0.0027                                     543                                                                   
  *hsa-miR-486-5p*    −0.0006,−0.0008                             953, 1090                                                             
  7\.                 *CD133*                                     *hsa-miR-532-3p*                 −0.0024                              365
  *has-miR-142-5p*    −0.0098                                     503                                                                   
  *has-miR-146b-5p*   −0.0030,−0.008, −0.0109, −0.0249 −0.0017,   1355, 2166, 2433, 2800                                                
  *hsa-miR-146b-3p*   −0.0010                                     975, 1621                                                             
  *has-miR-328*       −0.1154                                     190                                                                   
  *hsa-miR-532-5p*    −0.0035                                     1076                                                                  
  *hsa-miR-142-3p*    −0.9794                                     272                                                                   
  *has-miR-142-5p*    −0.8091                                     604                                                                   
  *hsa-miR-486-5p*    −0.0224                                     392                                                                   
  9\.                 *P53*                                       *hsa-miR-532-3p*                 −0.0687                              235
  *has-miR-146b-5p*   −0.0017                                     88                                                                    
  *hsa-miR-146b-3p*   −0.0016                                     176                                                                   
  10\.                *Mdm2*                                      *hsa-miR-532-5p*                 −0.0057, −0.0002, −0.0006 −0.0017,   555, 783, 1122
  *hsa-miR-142-5p*    −0.0014, −0.0011, −0.0023, −0.0003,         1707, 2868,                                                           
  *hsa-miR-146b-5p*   −0.0005 −0.0001,−0.0001, −0.0003,           3158, 4279, 5297, 4557                                                
  *hsa-miR-486-5p*    −0.0002, −0.0000                            553, 778, 1119, 1510, 5177                                            

###### 

miRNA expression to normal cadaveric donor retina of RB primary tumor tissues with the clinicopathological description.

  RB TUMOR NUMBERS   AGE (YRS)/SEX   RB GROUP (IIRC) CLASSIFICATION   CLINICO-PATHOLOGICAL DESCRIPTIONS                *miR-142*   *miR-146b*   *miR-328*   *miR-486-3p*   *miR-582-5p*
  ------------------ --------------- -------------------------------- ------------------------------------------------ ----------- ------------ ----------- -------------- --------------
  RB1                3Y/F            B                                OS:WD, NI                                        −14.59      −8.11        −8.36       −14.85         −8.24
  RB2                2Y/F            D                                OS:PD, NI                                        −14.03      −8.52        −6.38       −14.75         −5.65
  RB3                8 mon/F         D                                OD:PD, NI                                        4.51        7.51         5.39        3.16           −3.77
  RB4                1Y/M            D                                OD:WD, No CI, Post-lam inv                       5.01        5.44         4.80        2.67           −5.18
  RB5                8 mon/M         B                                OS: WD, NI                                       −5.56       −4.00        −5.31       −8.86          −0.96
  RB6                2Y/F            D                                OD: PD, NI                                       −15.27      −13.14       −13.17      −14.18         −9.46
  RB7                3Y/F            D                                OD: WD focal RPE Inv, CI \<3 mm                  0.30        0.14         0.12        −0.24          0.09
  RB8                3Y/M            D                                OD: MD, focal RPE, minimal post-lam inv          −0.17       −0.35        −0.39       −0.90          −0.58
  RB9                7Y/F            D                                OS: MD, NI                                       0.53        1.19         −0.42       0.17           0.22
  RB10               2Y/F            D                                OD: WD, RPE, CI \<3 mm                           −1.19       −1.23        −1.21       −2.14          −0.83
  RB11               2Y/M            B                                OD: WD, NI                                       −0.11       −0.19        −0.48       −0.83          −0.50
  RB12               2Y/F            D                                OS: PD, NI                                       −0.64       −0.93        −1.34       −1.53          −1.38
  RB13               2Y/M            D                                OS: PD, NI                                       −1.44       −1.46        −2.14       −1.93          −2.01
  RB14               2Y/F            E                                OS: MD, CI \>3 mm, pre-lam inv                   −12.69      −8.82        −8.30       −13.41         −4.90
  RB15               6Y/F            E                                OD:WD, focal CI \<3 mm, pre-lam inv              −11.83      −8.17        −7.91       −10.97         −8.01
  RB16               4Y/M            E                                OS:PD, CI \>3 mm, pre-lam, scleral inv           −13.47      −7.36        −13.23      −13.10         −6.54
  RB17               4Y/M            E                                OD:PD, CI \>3 mm, post-lam ON                    2.69        5.51         2.61        0.21           −8.22
  RB18               11Y/F           D                                OS: PD, CI \<3mm,                                −15.70      −13.32       −9.10       −15.81         −11.18
  RB19               3Y/M            D                                OS: PD, No CI post-lam ON                        −0.18       −0.34        −0.53       −1.00          −0.69
  RB20               1Y/M            E                                OS: MD, CI \>3 mm, pre-lam                       0.23        0.04         0.01        −0.51          −0.14
  RB21               3Y/M            E                                OS: PD, CI \>3 mm, pre-lam and post-lam ON inv   0.02        −0.20        −0.30       −0.89          −0.51
  RB22               9 mon/M         E                                OS: MD, CI \<3 mm, pre-lam                       −0.16       −0.86        −0.38       −1.40          −0.57
  RB23               2Y/F            E                                OD: MD, CI \>3 mm                                0.29        0.11         0.08        −0.44          −0.12
  RB24               4Y/M            E                                OS: PD, CI \>3 mm, pre-lam and post-lam inv      −0.49       −0.67        −0.71       −1.22          −0.90
  RB25               4Y/F            D                                OS: WD,CI \<3 mm                                 −0.57       −0.74        −0.90       −1.26          −0.69
  RB26               4Y/F            D                                OD: UD, CI \>3 mm, pre-lam inv                   0.06        −0.12        −0.85       −2.12          −0.53
  RB27               1Y/F            B                                OD: MD, CI \<3 mm                                −1.78       −1.75        −1.96       −2.65          −1.97
  RB28               2Y/M            B                                OS: MD, No CI, pre-lam and post-lam inv          −0.55       −0.53        −0.86       −1.43          −0.66
  RB29               3Y/M            B                                OS: MD,CI \<3 mm, pre-lam inv                    2.21        −0.83        1.47        0.02           −0.24
  RB30               4Y/M            D                                OD: MD, CI \<3 mm, pre-lam inv                   0.79        −1.21        0.62        −0.77          −1.05

**Abbreviations:** M, Male; F, Female; OD, Right eye; OS, Left eye; RPE, Retinal Pigment epithelium; CI, Choroidal invasion; pre-lam, Pre-laminar; post-lam, Post-laminar; inv, Invasion; ON, optic nerve.

###### 

Fold change of select miRNAs (*n* = 5) in RB cell lines (Y79 and Weri Rb1), RB primary tumors (invasion/no invasion) and in normal cadaveric donor retinae.

  miRNAs          MEAN FOLD CHANGE IN log~2~ RATIO (SD)   MEDIAN FOLD CHANGE IN log~2~ RATIO                     
  --------------- --------------------------------------- ------------------------------------ -------- -------- -------
  *miR-486--3p*   −1.921 (0.5)                            −1.868 (0.2)                         −1.261   −1.079   0.01
  *miR-532--5p*   −1.765 (0.5)                            −1.775 (0.3)                         −0.694   −1.006   −0.19
  *miR-142--5p*   −0.985 (0.4)                            −0.870 (0.2)                         −0.182   −0.176   0.35
  *miR-146--5p*   −1.395 (0.5)                            −1.877 (0.2)                         −0.737   −0.877   0.27
  *miR-328*       −2.090 (0.6)                            −1.922 (0.2)                         −0.705   −0.593   0.41

###### 

Fold decrease in *SYK* and *FASN* mRNA in the miRNA mimic-transfected RB cells.

  TREATMENT WITH miRNA MIMICS   Y79-*SYK* (SD)   Y79-*FASN* (SD)   Weri Rb1-*SYK* (SD)   Weri Rb1-*FASN* (SD)
  ----------------------------- ---------------- ----------------- --------------------- ----------------------
  *miR-486--3p-24*              −2.2 (0.3)       −1.8 (1.0)        −3.4 (1.7)            0.8 (2.0)
  *miR-532--5p-24*              −0.6 (0.3)       −0.6 (0.2)        8.1 (0.1)             4.9 (0.1)
  *miR-486--3p-48*              −2.2 (1.1)       −2.6 (0.3)        −3.4 (1.0)            −0.3 (0.5)
  *miR-532--5p-48*              −4.7 (2.1)       −1.2 (0.4)        −8.7 (1.0)            −1.7 (2.2)
  *miR-486--3p-72*              0.6 (0.1)        1.9 (0.2)         3.9 (0.8)             0.4 (1.6)
  *miR-532--5p-72*              0.1 (0.1)        0.5 (0.2)         3.3 (1.3)             −0.7 (1.1)
